Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study.
Melissa Y Y MoeyDarla K LilesBlase A CarabelloPublished in: Cardio-oncology (London, England) (2019)
Our data suggest that the concurrent use of a RAAS inhibitors during TRA treatment may provide a protective effect against TIC and warrants further investigation. The low sensitivity and positive predictive value demonstrated that the CRS has minimal utility as a screening tool for prediction of patients at high risk for TIC. Therefore, closer surveillance of patients receiving TRA is warranted for early detection of TIC.
Keyphrases
- obsessive compulsive disorder
- end stage renal disease
- ejection fraction
- chronic kidney disease
- angiotensin ii
- newly diagnosed
- angiotensin converting enzyme
- public health
- prognostic factors
- electronic health record
- big data
- epidermal growth factor receptor
- patient reported outcomes
- oxidative stress
- drug induced
- stress induced
- data analysis